Who Responds Best to Tirzepatide? Predictors From the SURPASS-4 Trial | Research

The takeaway

75-84% of tirzepatide responders sustained blood sugar control through 81 weeks, with shorter diabetes duration, higher dose, and greater weight loss predicting lasting success.

75-84% sustained response
Most patients who achieved blood sugar goals on tirzepatide at 52 weeks maintained them through 81 weeks

What the researchers found

75-84% of tirzepatide responders sustained HbA1c ≤6.5% through median 81 weeks; predictors included higher dose, shorter diabetes duration, better baseline beta-cell function, and greater weight loss.

Why it matters

Knowing which patients will respond best to tirzepatide helps clinicians personalize treatment decisions, start the right patients earlier, and set realistic expectations about long-term outcomes.

The numbers in context

75-84% sustained HbA1c <= 6.5% from week 52 to study end (median 81 weeks). 79-82% maintained >= 10% weight loss. Predictors: higher dose, shorter diabetes duration, lower baseline HbA1c, higher HOMA-B, metformin alone, no albuminuria, female sex.

How the study worked

Post hoc analysis of the SURPASS-4 randomized trial in people with type 2 diabetes and increased cardiovascular risk, evaluating predictors of initial and sustained glycemic and weight response to tirzepatide.

Who was studied

Adults with type 2 diabetes and increased cardiovascular risk from SURPASS-4

What this study cannot tell us

Post hoc analysis — findings are hypothesis-generating, not confirmatory. Results are from a specific trial population with cardiovascular risk and may not generalize to all T2D patients.

How to read the evidence

Post hoc analysis of a major randomized trial — provides strong signal but cannot prove causation for the predictive factors. Prospective validation would strengthen these findings.

When this study was published

Published in 2025, providing extended follow-up analysis from the landmark SURPASS-4 trial.

The bigger picture

This analysis supports the concept of early intervention — patients with newer diabetes and better-preserved beta-cell function get the most lasting benefit from tirzepatide, reinforcing the importance of timely treatment initiation.

Questions still open

Should tirzepatide be recommended earlier in the diabetes treatment course based on these predictors?
Do similar predictors apply to semaglutide and other GLP-1 receptor agonists?

Common questions

Who is most likely to respond well to tirzepatide?

Based on this analysis, patients with shorter diabetes duration, lower starting HbA1c, better beta-cell function, and those on metformin alone (without other diabetes drugs) had the best chance of achieving and maintaining blood sugar goals.

Does the benefit of tirzepatide last over time?

For most responders, yes. 75-84% of patients who achieved HbA1c ≤6.5% at one year maintained that level through the end of the study at about 81 weeks. Achieving greater weight loss helped sustain the blood sugar benefit.

Read the original research

Predictors of Initial and Sustained Glycemic and Weight Response to Tirzepatide: A Post Hoc Analysis of SURPASS-4.

Diabetes, 74(10), 1850-1862

View on PubMed ↗Publisher’s paper ↗

Citation

Pearson, Ewan R; Del Prato, Stefano; Pavo, Imre; Franco, Denise R; Zheng, Junyuan; Nicolay, Claudia; Hemmingway, Andrea; Wiese, Russell J; Kahn, Steven E. (2025). Predictors of Initial and Sustained Glycemic and Weight Response to Tirzepatide: A Post Hoc Analysis of SURPASS-4.. Diabetes, 74(10), 1850-1862. https://doi.org/10.2337/db25-0276